Order Article Reprints

Erelel M, Kaskal M, Akbal-Dagistan O, Issever H, Dagistanli AS, Balkanci H, Oguz MS, Qarayeva A, Culha M, Erturk A, et al. Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial. Pharmaceutics. 2021; 13(11):1768. https://doi.org/10.3390/pharmaceutics13111768

Erelel, Mustafa, Mert Kaskal, Ozlem Akbal-Dagistan, Halim Issever, Ahmet Serhan Dagistanli, Hilal Balkanci, Merve Sinem Oguz, Aygun Qarayeva, Meltem Culha, Aybige Erturk, and et al. 2021. "Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial" Pharmaceutics 13, no. 11: 1768. https://doi.org/10.3390/pharmaceutics13111768

Erelel, M., Kaskal, M., Akbal-Dagistan, O., Issever, H., Dagistanli, A. S., Balkanci, H., Oguz, M. S., Qarayeva, A., Culha, M., Erturk, A., Basarir, N. S., Sahin, G., Uresin, A. Y., Araman, A. O., Medetalibeyoglu, A., Tukek, T., Oncul, M. O., & Yildiz-Pekoz, A. (2021). Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial. Pharmaceutics, 13(11), 1768. https://doi.org/10.3390/pharmaceutics13111768